Business Context and Reporting Period
Company: Inmed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 22, 2024
Reporting Period: Single event date (October 22, 2024)
Business Context: The company is an emerging growth company incorporated in British Columbia, Canada, with principal executive offices in Vancouver. It is listed on The Nasdaq Stock Market LLC under the symbol "INM".
Key Financial Metrics
This filing is a current report regarding a corporate governance event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported in this filing is the appointment of a new member to the Scientific Advisory Board:
- Appointee: Dr. Barry Greenberg.
- Role: Director of the Alzheimer's Disease Translational Center and Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine.
- Effective Date: October 22, 2024.
Guidance, Outlook, and Risks
This filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard disclosure language regarding the non-filing status of the press release. The information provided in Item 7.01 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the official press release (Exhibit 99.1) for detailed biographical information on Dr. Barry Greenberg.
- Confirm the impact of this appointment on the company's ongoing research and development pipeline for Alzheimer's disease.
- Review the company's most recent 10-K or 10-Q filings for the latest financial position, as this 8-K contains no financial data.